Comprehensive Analysis of Environmental Monitoring Data from the Department of Nuclear Medicine and Molecular Imaging (NMMI) of the University Medical Center Groningen (UMCG)

Author:

Boersma Hendrikus H.12ORCID,Woerdenbag Mirte M.1,Mulder Sascha1,Poiesz Tirza W. T.3,Bekhof Lucas B. S.3,Tholen Hein T.1,Luurtsema Gert1ORCID,Lub-de Hooge Marjolijn N.12ORCID,Giesen Danique1,Woerdenbag Herman J.3ORCID

Affiliation:

1. Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen (UMCG), Hanzeplein 1, 9713 GZ Groningen, The Netherlands

2. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen (UMCG), Hanzeplein 1, 9713 GZ Groningen, The Netherlands

3. Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands

Abstract

Environmental monitoring (EM) is the cornerstone for the assurance of sterility during aseptic manufacturing. In this study, the EM quality aspects in the radiopharmaceutical cleanrooms of the University Medical Center Groningen (UMCG), The Netherlands, were evaluated. Hereto, data obtained from EM over the period 2010–2022 were analyzed. The data were sorted according to the Good Manufacturing Practice (GMP) classification of the respective premises with their corresponding limits, and frequencies of excursions were determined per location. The frequency of conducted measurements gradually increased between the start and end of the assessed period. There was a trend of increased action limit excursions observed between 2010–2022. We found that EM in grade A areas appeared to be significantly less compliant with GMP specifications than the combined data from all sampled premises at the facility (p < 0.00001; two-sided Fisher’s exact test). A trend was found for reduced action limit excursions for passive air sampling and particle counting, suggesting improved GMP compliance over time for this specific type of EM. The contamination recovery rate (CRR) found for cleanroom conditions, around 10%, was considered sufficient. From this comprehensive data analysis, we learn that, in order to be fully compliant with the requirements set in the recent revision of EU (European Union)-GMP Annex 1 ‘Manufacture of sterile medicinal products’ (in force as of 25 August 2023), strategies to further improve product protection are justified. For example, improved cleaning and disinfection procedures, more efficient working methods as well as optimization of the conditions under which aseptic manufacturing is performed are to be considered.

Publisher

MDPI AG

Reference19 articles.

1. European Commission (2022). The Rules Governing Medicinal Products in the European Union. Volume 4. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Directorate-General for Health and Food Safety. Available online: https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en.

2. United States Food and Drugs Administration (US FDA) (2024, May 17). Current Good Manufacturing Practice (CGMP) Regulations, Available online: https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations.

3. World Health Organization (WHO) (2024, May 17). Health Products Policy and Standards. Good Manufacturing Practices. Available online: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/gmp.

4. European Commission (2008). Annex 1. Manufacture of sterile medicinal products. The Rules Governing Medicinal Products in the European Union. Volume 4. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Directorate-General for Health and Food Safety. Available online: https://health.ec.europa.eu/system/files/2016-11/2008_11_25_gmp-an1_en_0.pdf.

5. European Commission (2022). Annex 1. Manufacture of sterile medicinal products. The Rules Governing Medicinal Products in the European Union. Volume 4. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Directorate-General for Health and Food Safety. Available online: https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3